Baseline resistance to nucleoside reverse transcriptase inhibitors fails to predict virologic response to combination therapy in children (PACTG 338)

Geahča maid

• Sensitive assessment of the virologic outcomes of stopping and restarting non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
  Dahkki: Anna Maria Geretti, et al.
  Almmustuhtton: (2013-01-01)
• Efficacy and safety of novel russian non-nucleoside reverse transcriptase inhibitor elsulfavirine in combination with 2 nucleoside/nucleotide reverse transcriptase inhibitors in first-line HIV treatment – 96-week study
  Dahkki: A. V. Kravchenko, et al.
  Almmustuhtton: (2018-07-01)
• First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial.
  Dahkki: Babiker, A, et al.
  Almmustuhtton: (2011)
• HTLV-1 reverse transcriptase homology model provides structural basis for sensitivity to existing nucleoside/nucleotide reverse transcriptase inhibitors
  Dahkki: Nicolas Tardiota, et al.
  Almmustuhtton: (2024-01-01)
• Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors.
  Dahkki: Esnouf, R, et al.
  Almmustuhtton: (1995)